Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease

NCT02240693 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02240693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02240693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
January 15, 2015
Completion date
October 9, 2017
Enrollment
128 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease